Article

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)

Department of Pediatrics, Baylor College of Medicine, Houston, Texas, United States
Blood (Impact Factor: 10.43). 12/2006; 108(9):2942-9. DOI: 10.1182/blood-2006-05-021782
Source: PubMed

ABSTRACT We have investigated the in vivo safety, efficacy, and persistence of autologous Epstein Barr virus (EBV)-specific cytotoxic T lymphocytes (CTLs) for the treatment of solid organ transplant (SOT) recipients at high risk for EBV-associated posttransplantation lymphoproliferative disease (PTLD). EBV-CTLs generated from 35 patients expanded with normal kinetics contained both CD8 and CD4 lymphocytes and produced significant specific killing of autologous EBV-transformed B lymphoblastoid cell lines (LCLs). Twelve SOT recipients at high risk for PTLD, or with active disease, received autologous CTL infusions without toxicity. Real-time polymerase chain reaction (PCR) monitoring of EBV-DNA showed a transient increase in plasma EBV-DNA suggestive of lysis of EBV-infected cells, although there was no consistent decrease in virus load in peripheral-blood mononuclear cells. Interferon-gamma enzyme-linked immunospot (ELISPOT) assay and tetramer analysis showed an increase in the frequency of EBV-responsive T cells, which returned to preinfusion levels after 2 to 6 months. None of the treated patients developed PTLD. One patient with liver PTLD showed a complete response, and one with ocular disease has had a partial response stable for over one year. These data are consistent with an expansion and persistence of adoptively transferred EBV-CTLs that is limited in the presence of continued immunosuppression but that nonetheless produces clinically useful antiviral activity.

Download full-text

Full-text

Available from: Stephan Schubert, Jan 12, 2014
1 Follower
 · 
162 Views
  • Source
    • "An alternative method to overcome the low frequency of tumor reactive T cells in autologous products that is being explored is gene transfer of T-cell receptors known to recognize tumor antigens into cells with cytotoxic potential, such as T cells or NK cells [79] [80] [81]. Although there has been much progress in the area of autologous adoptive immunotherapy for cancer in adults, there are limited data in pediatric patients [82]. Another approach that can be used alone or in combination with adoptive T-cell therapy is the use of vaccines to expand tumor-reactive T cells. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The past 25 years have seen an increase in our understanding of immunology and further expansion in the clinical use of immunotherapeutic modalities. How immunotherapy will be integrated with chemotherapy, radiation, and surgery remains to be established. Although there have been successes in the field of immunotherapy, they have been inconsistent, and it is hoped that increased understanding of the basic principles of immunology will improve the consistency of beneficial effects. In this article, we briefly provide a general overview of our current understanding of the immune system, with a focus on concepts in tumor immunology, followed by a discussion of how these concepts are being used in the clinic.
    Hematology/oncology clinics of North America 02/2010; 24(1):109-27. DOI:10.1016/j.hoc.2009.11.010 · 2.07 Impact Factor
  • Source
    • "Reduction of immunosupression, radiotherapy , chemotherapy, surgery and monoclonal antibody-based regimens (Swinnen et al, 1995; Choquet et al, 2006) are routinely used to treat the disease on presentation of tumour, but even with such treatment options the mortality rate is approximately 50% (Opelz and Dohler, 2004; Choquet et al, 2007). More recently, infusions of ex-vivo expanded EBV-specific CTLs to selectively reconstitute EBV-specific immunity have proven useful in the treatment and prevention of EBV-positive PTLD (Savoldo et al, 2006; Haque et al, 2007). Strategies to predict the impending development of PTLD allowing early and effective intervention are therefore assuming increasing importance. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Epstein-Barr virus-positive post-transplant lymphoproliferative disease (PTLD) is a potentially lethal complication of iatrogenic immunosupression after transplantation. Predicting the development of PTLD allowing early and effective intervention is therefore of importance. Polymorphisms within cytokine genes are implicated in susceptibility to, and progression of, disease however the published data are often conflicting. We undertook investigation of polymorphic alleles within cytokine genes in PTLD and non-PTLD transplant cohorts to determine risk factors for disease. SSP-PCR was used to analyse single nucleotide polymorphism within tumour necrosis factor (TNF)-alpha, interleukin- 1, -6, -10 and lymphotoxin-alpha genes. The TNF-alpha levels were measured by standard enzyme-linked immuno-absorbant assay. We show an association between variant alleles within the TNF-alpha promoter (-1031C (P=0.005)); -863A (P=0.0001) and TNF receptor I promoter regions (-201T (P=0.02)); -1135C (P=0.03) with the development of PTLD. We also show an association with TNF-alpha promoter haplotypes with haplotype-3 significantly increased (P=0.0001) and haplotype-1 decreased (P=0.02) in PTLD patients compared to transplant controls. Furthermore, we show a significant increase (P=0.02) in the level of TNF-alpha in PTLD patient plasma (range 0-97.97 pg ml(-1)) compared to transplant controls (0-8.147 pg ml(-1)), with the highest levels found in individuals carrying the variant alleles. We suggest that genetic variation within TNF-alpha loci and the level of plasma cytokine could be used as a predictive risk factor for the development of PTLD.
    British Journal of Cancer 10/2009; 101(6):1019-27. DOI:10.1038/sj.bjc.6605278 · 4.82 Impact Factor
  • Source
    • "Interferon-gamma enzyme-linked immunospot assay and tetramer analysis showed an increase in the frequency of EBV-responsive T cells. None of the patients at risk for PTLD developed the disease, one patient with PTLD had a complete response, and one with PTLD had a partial response‥ However, this approach is highly labor-intensive as a specific autologous cell line has to be prepared for each patient [Savoldo 2006]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A heterogeneous group of malignancies are associated with Epstein-Barr virus (EBV) infection. These malignancies arise in both immunosuppressed and immunocompetent individuals and can be divided into three patterns of latency depending on the viral genes that are expressed. In Type III latency malignancies, such as post-transplant lymphoproliferative disorder (PTLD), EBV has a direct role and the activated B-cell phenotype is characterised by high-level expression of all the immunodominant EBV latency proteins. Thus, EBV-infected B cells are good targets for EBV-specific cytotoxic T lymphocytes (CTLs). New immune-based treatments for PTLD include transfer of ex vivo generated autologous EBV-specific CTLs or, in the case of bone marrow transplant recipients, donor-derived EBV-specific T cells. This strategy could, perhaps, also work in Type II latency malignancies, where EBV acts like a cofactor rather than having a direct role. In initial studies, T cells specific for the weakly immunogenic latent membrane protein 2 have been expanded ex vivo and have promoted tumor regression in a subset of patients. Another potential therapeutic strategy could be to try to induce lytic EBV infection in the tumor cells. This could be done by targeting genes that switch the EBV-infected B cells from the latent to the lytic cycle.
    Leukemia & lymphoma 01/2008; 49 Suppl 1(1):27-34. DOI:10.1080/10428190802311417 · 2.89 Impact Factor
Show more